4D Molecular Therapeutics, Inc. (FDMT:NASDAQ) closed at $10.72 on November 19, 2026, up 2.49% on the day. The stock trades 36.7% below its 52-week high of $16.93 and 54.0% above its 52-week low of $6.96. Over the past year, it gained 3.7%. 4D Molecular Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 19, 2025, FDMT closed higher on 130 days (52%). Its best day was August 17, 2026 (+19.32%) and its worst was December 17, 2025 (-20.05%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 1 time.
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Find more stocks like FDMT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.